Posts by: Alice Melão

News

A new method that selects and isolates malignant myeloma cells based on their size and molecular markers enables more precise detection of chromosomal abnormalities, University of Southern California researchers ... Read more

April 20, 2018

P-BCMA-101 Shows Early Effectiveness in First Multiple Myeloma Patients Treated in Phase 1 Trial

News

P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy, is safe and effective in relapsed or refractory multiple myeloma patients, results from the first three patients enrolled in a Phase 1 trial show. ... Read more

April 18, 2018

Seattle Genetics’ Investigational Therapy Fares Well in Multiple Myeloma Animal Models

News

A new antibody targeting the BCMA protein — called SEA-BCMA — has shown promising effectiveness and safety results in animal models of multiple myeloma, making it a strong candidate ... Read more

April 11, 2018

China FDA Prepares to Review Evomela for Approval in Multiple Myeloma Treatment

News

Multiple myeloma patients in China may soon have access to an injectable formulation of melphalan, called Evomela, as the China Food and Drug Administration (CFDA) prepares to review CASI ... Read more

April 2, 2018April 2, 2018

Bluebird Bio and Celgene Partner to Advance bb2121, Potential Multiple Myeloma CAR T-cell Therapy

News

The investigational therapy bb2121, a possible treatment for relapsed or refractory multiple myeloma patients, is advancing in clinical testing under a recently announced partnership between bluebird bio and Celgene. The companies ... Read more

February 26, 2018February 26, 2018

Revlimid Combo Treatment Improved Survival in Newly-diagnosed Myeloma Patients in Phase 3 Trial

News

Newly diagnosed multiple myeloma patients unable to undergo stem cell transplants lived significantly longer without their disease progressing when given continuous treatment with Revlimid (lenalidomide) and low-dose dexamethasone, compared ... Read more

February 14, 2018

PT-112 Receives Orphan Drug Status for Advanced Multiple Myeloma

News

PT-112, an investigational small molecule that promotes cancer cell death, has been designated an orphan drug by the U.S. Food and Drug Administration (FDA) for the treatment of multiple ... Read more

February 5, 2018February 5, 2018

Ethyol Pretreatment Reduces Gastrointestinal Side Effects of Bone Marrow Transplant in Myeloma Patients

News

Pretreating multiple myeloma patients with Ethyol (amifostine) prior to a stem cell transplant significantly reduces the transplant therapy’s gastrointestinal toxicity without compromising its efficacy, a new study shows. The study, ... Read more

February 2, 2018February 2, 2018

Myeloma Research Foundation and Karyopharm Hoping Myeloma Therapy Progress Continues

News

The Multiple Myeloma Research Foundation and Karyopharm Therapeutics are hoping that 2018 will be as momentous a year as 2017 in their collaborative effort to develop a new treatment for multiple myeloma ... Read more

January 29, 2018

Selinexor, Dexamethasone Combo Shows Promise in Heavily Treated Myeloma Patients

News

Multiple myeloma patients who received several prior lines of therapy showed promising response rates when treated with a combination of Karyopharm Therapeutics‘ selinexor and dexamethasone, a Phase 1 trial showed. ... Read more